Details
| Stereochemistry | UNKNOWN |
| Molecular Formula | C19H35N.C4H4O4 |
| Molecular Weight | 393.5601 |
| Optical Activity | ( - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C/C(O)=O.C(C(C1CCCCC1)C2CCCCC2)C3CCCCN3
InChI
InChIKey=JDZOTSLZMQDFLG-BTJKTKAUSA-N
InChI=1S/C19H35N.C4H4O4/c1-3-9-16(10-4-1)19(17-11-5-2-6-12-17)15-18-13-7-8-14-20-18;5-3(6)1-2-4(7)8/h16-20H,1-15H2;1-2H,(H,5,6)(H,7,8)/b;2-1-
Perhexiline, 2-(2,2-dicyclohexylethyl)piperidine, is an anti-anginal drug. Perhexiline reduces fatty acid metabolism through the inhibition of carnitine palmitoyltransferase, the enzyme responsible for mitochondrial uptake of long-chain fatty acids. Perhexiline is used for reducing the frequency of moderate to severe attacks of angina pectoris due to coronary artery disease in patients who have not responded to other conventional therapy or in whom such therapy may be contraindicated. Heart Metabolics Limited is developing perhexiline for the treatment of hypertrophic cardiomyopathy
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL3858 |
77.0 µM [IC50] | ||
Target ID: CHEMBL3216 |
148.0 µM [IC50] | ||
Target ID: CHEMBL240 |
7.8 µM [IC50] | ||
Target ID: CHEMBL4306 |
1.5 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | PEXSIG Approved UseTo reduce the frequency of moderate to severe attacks of angina pectoris due to coronary artery disease in patients who have not responded to other conventional therapy or in whom such therapy may be contraindicated. Launch Date1977 |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Electrophysiological study of latent neuropathies induced by perhexiline]. | 1978 Nov |
|
| [The classic anti-anginal agents and molsidomine]. | 1983 Feb |
|
| Perhexilene neuropathy: a report of two cases. | 1984 Jun |
|
| Therapeutic drug monitoring: antiarrhythmic drugs. | 2001 |
|
| Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose. | 2002 Aug |
|
| The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. | 2002 Nov |
|
| Association of aortic stenosis with platelet hyperaggregability and impaired responsiveness to nitric oxide. | 2002 Sep 1 |
|
| A new hepatoma cell line for toxicity testing at repeated doses. | 2003 Apr |
|
| Polymorphic hydroxylation of perhexiline in vitro. | 2003 Jun |
|
| Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline. | 2004 Apr |
|
| Theoretical possibilities for the development of novel antiarrhythmic drugs. | 2004 Jan |
|
| Influence of different calcic antagonists on the Caco-2 cell monolayer integrity or "TEER, a measurement of toxicity?". | 2005 Jan-Jun |
|
| Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice? | 2005 May |
|
| Effect of the anti-anginal agent, perhexiline, on neutrophil, valvular and vascular superoxide formation. | 2006 Feb 15 |
|
| Enantioselective assay for the determination of perhexiline enantiomers in human plasma by liquid chromatography. | 2006 Feb 17 |
|
| Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. | 2007 Mar |
|
| Impaired tissue responsiveness to organic nitrates and nitric oxide: a new therapeutic frontier? | 2007 Nov |
|
| Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition. | 2008 Dec |
|
| Management of the metabolic syndrome in cardiovascular disease. | 2008 Feb |
|
| Overview of emerging pharmacologic agents for acute heart failure syndromes. | 2008 Feb |
|
| Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment. | 2008 Feb |
|
| Metabolic agents in the management of diabetic coronary patients: a new era. | 2008 Jun 23 |
|
| Ca2+-dependent functions in peptidoglycan-stimulated mouse dendritic cells. | 2009 |
|
| Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond. | 2009 Dec |
|
| Prediction of pharmacological and xenobiotic responses to drugs based on time course gene expression profiles. | 2009 Dec 2 |
|
| The adrenergic-fatty acid load in heart failure. | 2009 Oct 27 |
|
| Stereoselective Inhibition of the hERG1 Potassium Channel. | 2010 |
|
| Chemical inducers of autophagy that enhance the clearance of mutant proteins in neurodegenerative diseases. | 2010 Apr 9 |
|
| A novel screen using the Reck tumor suppressor gene promoter detects both conventional and metastasis-suppressing anticancer drugs. | 2010 Aug |
|
| Niclosamide prevents the formation of large ubiquitin-containing aggregates caused by proteasome inhibition. | 2010 Dec 23 |
|
| The pathophysiology of diastolic heart failure. | 2010 Feb 24 |
|
| Modulation of myocardial metabolism: an emerging therapeutic principle. | 2010 Jul |
|
| Metabolic Fingerprinting in Toxicological Assessment Using FT-ICR MS. | 2010 Jun |
|
| Lack of effect of perhexiline in ischaemic heart failure. | 2010 Mar 4 |
|
| Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. | 2010 Nov 16 |
|
| Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. | 2010 Oct 19 |
|
| Perhexiline and hypertrophic cardiomyopathy: a new horizon for metabolic modulation. | 2010 Oct 19 |
|
| Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
|
| Comparison of a genomic and a multiplex cell imaging approach for the detection of phospholipidosis. | 2011 Oct |
Patents
Sample Use Guides
Commence therapy with 100mg daily. Adjust progressively, up or down, at 2 to 4 weekly intervals based on the results of plasma level monitoring. It is generally advised not to administer more than 300mg per day, in divided doses, but in certain cases it may be necessary to use 400mg per day. The maintenance dose must be the minimum dose that is effective and well tolerated.
Route of Administration:
Oral
Perhexiline maleate was more potent on basal LH release from rat anterior pituitary cell aggregates than on LH stimulated by LHRH. The increases of basal LH secretion induced by perhexiline maleate were 69% (p < 0.001) at a concentration of 10(-7)M, 130% (p < 0.001) at a concentration of 10(-5)M and 250% (p < 0.001) at a concentration of 10(-4)M. Perhexiline maleate also increased the LHRH-stimulated LH release by 25.5% (p < 0.05) at a concentration of 10(-5)M and by 74.5% (p < 0.01) at the concentration of 10(-4)M.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9GN57XTP25
Created by
admin on Sat Dec 16 10:32:49 GMT 2023 , Edited by admin on Sat Dec 16 10:32:49 GMT 2023
|
PRIMARY | |||
|
103516-76-3
Created by
admin on Sat Dec 16 10:32:49 GMT 2023 , Edited by admin on Sat Dec 16 10:32:49 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD
